Core Viewpoint - China Traditional Chinese Medicine (00570) is expected to report a net loss for the fiscal year ending December 31, 2025, with losses projected between RMB 350 million and 500 million, a significant decline from a net profit of RMB 20.77 million in the same period last year [1] Group 1: Financial Performance - The adjusted net profit for the current period is expected to decrease by 45% to 55%, compared to approximately RMB 635.5 million in the previous year [1] - The company’s stock has dropped over 4%, currently trading at HKD 2.09, with a trading volume of HKD 11.2992 million [1] Group 2: Reasons for Loss - The transition from profit to loss is primarily attributed to the increased proportion of centralized procurement in the Chinese medicine formula granule business, leading to a decline in revenue scale and profitability [1] - Additional factors contributing to the loss include impairment of goodwill, impairment of intangible assets, and increased credit impairment [1] - The adjusted net profit excludes impacts from goodwill and related asset group impairments, as well as tax payments made by certain subsidiaries [1]

Core Viewpoint - The company is focusing on collective procurement and high-quality clients while adapting to social, e-commerce, and new sales trends [1] Group 1: Business Strategy - The company is actively expanding its own brand through diversified sales channels, including live e-commerce [1] - The company emphasizes scenario-based marketing and communication to enhance brand visibility and customer engagement [1] - The strategy aims to bridge the gap between the brand and consumers, enhancing the overall customer experience [1]